Pediatric Neurocysticercosis Workup
- Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: Russell W Steele, MD more...
Laboratory diagnosis of neurocysticercosis is facilitated by serological and imaging studies.[18, 19]
Enzyme-linked immunotransfer blot assay
If neurocysticercosis is suspected on the basis of clinical and radiographic evidence, an enzyme-linked immunotransfer blot (EITB) assay of a patient's serum may confirm the diagnosis.
Specificity is 100% and sensitivity is 90% for children with more than 2 lesions. Sensitivity is only 50-70% in children with just one lesion (the majority); therefore, the usefulness of this test may be limited.
EITB can be ordered by sending serum to the state public health department laboratory in the area or to the Centers for Disease Control and Prevention (CDC). One private laboratory in the United States (Specialty Laboratories; Los Angeles, California) also performs the test. The CDC Web site provides further information.
HP10 antigen testing
Detection of the metacestode HP10 antigen in serum is a useful tool for diagnosis and follow-up of patients with severe forms of neurocysticercosis treated with cysticidal drugs.
Polymerase chain reaction
More recently, T solium DNA has been observed in the cerebrospinal fluid (CSF) of patients. The polymerase chain reaction amplification of the parasite DNA in the CSF enabled the investigators in correct identification of 29 cases (96.7%).
Examine stools from patients and their contacts for ova and parasites. Obtain 3 consecutive daily stool specimens.
The presence of ova may be the sole diagnostic confirmation in some children, but more importantly, detecting ova in children with neurocysticercosis is worthwhile as a public health measure to prevent further exposure to the tapeworm ova.
Stool test for T solium ova is rarely positive.
Enzyme-linked immunosorbent assay
Enzyme-linked immunosorbent assay (ELISA) can be used on serum and CSF. Detection of antigen in the CSF using a monoclonal antibody-based ELISA has been shown to increase the diagnostic sensitivity.
ELISA can aid in diagnosis in cases with few lesions and relatively mild disease.
CT scanning shows the cyst and granuloma stages of neurocysticercosis. These cysts can be solitary or multiple and are usually 5-20 mm in diameter.
Perform CT scanning on all children considered for the diagnosis. Most likely, CT scanning is performed upon presentation of a child with new-onset focal seizures. CT scanning can be performed without contrast.
Approximately 75% of children who are affected with neurocysticercosis have a solitary lesion. Lesions are located most often in the cortex or at the gray-white junction. Approximately one half of lesions have a punctate high density within the ring (scolex). Between 10-20% of children have no abnormality (also observed in MRI studies).
CT scanning is superior to MRI study in detecting calcification, which can be useful in differentiating the punctate cyst of neurocysticercosis in the granuloma wall from other causes of granulomas; however, calcification is observed less frequently in children than in adults. See the images below.
CT scanning can also detect edema around the cyst, which is associated with the death of the organism.
CT scanning can be performed quickly, which is important when caring for young children.
MRI is the best imaging test overall for the diagnosis. Perform MRI in all patients for whom the clinical history and CT scan findings suggest neurocysticercosis. Use gadolinium contrast.
MRI is useful for lesions of the spinal cord, posterior fossa, brainstem, subarachnoid, and ventricles.
Use of contrast also shows larval death, visible as enhancement of the cyst wall, which indicates that the cyst has changed into a granuloma. In addition, MRI (as well as CT scanning) shows any vasogenic edema around the cyst, indicative of the body's inflammatory response to organism death.
MRI can be used as follow-up imaging to document improvement based on both a decrease in the granuloma diameter and a resolution of vasogenic edema.
A 2000 study of 108 patients by Pradhan et al indicated the prognostic usefulness of gliosis as observed in a T1-weighted magnetization transfer spin-echo MRI. This gliosis was associated with seizure recurrence after at least 2 years of antiepileptic medications were tapered and then discontinued.
See the images below.
Soft tissue radiography can be performed to look for extraneural cysts.
Radiography is rarely helpful. Perform radiography only when all other tests have failed to provide a diagnosis.
For unknown reasons, children in the United States with neurocysticercosis rarely have cysts in subcutaneous or intramuscular tissue.
Skull radiography can be performed, although they are rarely helpful with the advent of the MRI. Occasionally, separation of the cranial sutures can be observed, which indicates increased intracranial pressure.
Perform electroencephalography (EEG) in children with recalcitrant seizures.
Occasionally, evidence of periodic lateralized epileptiform discharges (PLEDs) is present.
In approximately 50% of cases, a lumbar puncture can reveal pleocytosis (often lymphocytic, but occasionally eosinophilic), decreased glucose, increased protein, and elevated opening pressure. A lumbar puncture can help exclude other infectious or malignant diagnoses.
Serum EITB is more sensitive than the CSF EITB assay, so CSF testing is not usually indicated.
Brain biopsy can be performed in cases where the diagnosis remains questionable and the lesion has not resolved. The procedure may be indicated in areas of low prevalence.
Prasad KN, Prasad A, Verma A, Singh AK. Human cysticercosis and Indian scenario: a review. J Biosci. 2008 Nov. 33(4):571-82. [Medline].
Serpa JA, Yancey LS, White AC Jr. Advances in the diagnosis and management of neurocysticercosis. Expert Rev Anti Infect Ther. 2006 Dec. 4(6):1051-61. [Medline].
Shandera WX, Kass JS. Neurocysticercosis: current knowledge and advances. Curr Neurol Neurosci Rep. 2006 Nov. 6(6):453-9. [Medline].
Singhi P, Singhi S. Neurocysticercosis in children. J Child Neurol. 2004 Jul. 19(7):482-92. [Medline].
Sinha S, Sharma BS. Neurocysticercosis: A review of current status and management. J Clin Neurosci. 2009 Apr 24. [Medline].
Serpa JA, Graviss EA, Kass JS, White AC Jr. Neurocysticercosis in Houston, Texas: an update. Medicine (Baltimore). 2011 Jan. 90(1):81-6. [Medline].
Sorvillo F, Wilkins P, Shafir S, Eberhard M. Public health implications of cysticercosis acquired in the United States. Emerg Infect Dis. 2011 Jan. 17(1):1-6. [Medline].
Zee CS, Go JL, Kim PE, DiGiorgio CM. Imaging of neurocysticercosis. Neuroimaging Clin N Am. 2000 May. 10(2):391-407. [Medline].
Wallin MT, Kurtzke JF. Neurocysticercosis in the United States: review of an important emerging infection. Neurology. 2004 Nov 9. 63(9):1559-64. [Medline].
Garcia HH, Del Brutto OH,. Neurocysticercosis: updated concepts about an old disease. Lancet Neurol. 2005 Oct. 4(10):653-61. [Medline].
Chaoshuang L, Zhixin Z, Xiaohong W, Zhanlian H, Zhiliang G. Clinical analysis of 52 cases of neurocysticercosis. Trop Doct. 2008 Jul. 38(3):192-4. [Medline].
Jung H, Cardenas G, Sciutto E, Fleury A. Medical treatment for neurocysticercosis: drugs, indications and perspectives. Curr Top Med Chem. 2008. 8(5):424-33. [Medline].
Ruiz-Garcia M, Gonzalez-Astiazaran A, Rueda-Franco F. Neurocysticercosis in children. Clinical experience in 122 patients. Childs Nerv Syst. 1997 Nov-Dec. 13(11-12):608-12. [Medline].
Talukdar B, Saxena A, Popli VK. Neurocysticercosis in children: clinical characteristics and outcome. Ann Trop Paediatr. 2002 Dec. 22(4):333-9. [Medline].
Carabin H, Ndimubanzi PC, Budke CM, Nguyen H, Qian Y, Cowan LD, et al. Clinical manifestations associated with neurocysticercosis: a systematic review. PLoS Negl Trop Dis. 2011 May. 5(5):e1152. [Medline]. [Full Text].
Rosenfeld EA, Byrd SE, Shulman ST. Neurocysticercosis among children in Chicago. Clin Infect Dis. 1996 Aug. 23(2):262-8. [Medline].
Michelet L, Fleury A, Sciutto E, Kendjo E, Fragoso G, Paris L, et al. Human neurocysticercosis: comparison of different diagnostic tests using cerebrospinal fluid. J Clin Microbiol. 2011 Jan. 49(1):195-200. [Medline]. [Full Text].
Garg RK, Sinha MK. Multiple ring-enhancing lesions of the brain. J Postgrad Med. 2010 Oct-Dec. 56(4):307-16. [Medline].
Fleury A, Hernandez M, Avila M, et al. Detection of HP10 antigen in serum for diagnosis and follow-up of subarachnoidal and intraventricular human neurocysticercosis. J Neurol Neurosurg Psychiatry. 2007 Sep. 78(9):970-4. [Medline].
Almeida CR, Ojopi EP, Nunes CM, et al. Taenia solium DNA is present in the cerebrospinal fluid of neurocysticercosis patients and can be used for diagnosis. Eur Arch Psychiatry Clin Neurosci. 2006 Aug. 256(5):307-10. [Medline].
Rodriguez S, Dorny P, Tsang VC, Pretell EJ, Brandt J, Lescano AG. Detection of Taenia solium antigens and anti-T. solium antibodies in paired serum and cerebrospinal fluid samples from patients with intraparenchymal or extraparenchymal neurocysticercosis. J Infect Dis. 2009 May 1. 199(9):1345-52. [Medline].
Balaji J, D M. Clinical and Radiological Profile of Neurocysticercosis in South Indian Children. Indian J Pediatr. 2011 Mar 12. [Medline].
Figueroa JJ, Davis LE, Magalhaes A. Extraparenchymal neurocysticercosis in albuquerque, New Mexico. J Neuroimaging. 2011 Jan. 21(1):38-43. [Medline].
Odermatt P, Preux PM, Druet-Cabanac M. Treatment of neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2008 Sep. 79(9):978. [Medline].
Thussu A, Chattopadhyay A, Sawhney IM, Khandelwal N. Albendazole therapy for single small enhancing CT lesions (SSECTL) in the brain in epilepsy. J Neurol Neurosurg Psychiatry. 2008 Mar. 79(3):272-5. [Medline].
Carpio A, Kelvin EA, Bagiella E, Leslie D, Leon P, Andrews H. Effects of albendazole treatment on neurocysticercosis: a randomised controlled trial. J Neurol Neurosurg Psychiatry. 2008 Sep. 79(9):1050-5. [Medline].
Ramirez-Zamora A, Alarcon T. Management of neurocysticercosis. Neurol Res. 2010 Apr. 32(3):229-37. [Medline].
Abba K, Ramaratnam S, Ranganathan LN. Anthelmintics for people with neurocysticercosis. Cochrane Database Syst Rev. 2010 Jan 20. CD000215. [Medline].
Garcia HH, Gonzales I, Lescano AG, Bustos JA, Zimic M, Escalante D, et al. Efficacy of combined antiparasitic therapy with praziquantel and albendazole for neurocysticercosis: a double-blind, randomised controlled trial. Lancet Infect Dis. 2014 Aug. 14(8):687-95. [Medline]. [Full Text].
Del Brutto OH, Roos KL, Coffey CS, García HH. Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med. 2006 Jul 4. 145(1):43-51. [Medline].
Kaur S, Singhi P, Singhi S, Khandelwal N. Combination therapy with albendazole and praziquantel versus albendazole alone in children with seizures and single lesion neurocysticercosis: a randomized, placebo-controlled double blind trial. Pediatr Infect Dis J. 2009 May. 28(5):403-6. [Medline].
Matthaiou DK, Panos G, Adamidi ES, Falagas ME. Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials. PLoS Negl Trop Dis. 2008 Mar 12. 2(3):e194. [Medline]. [Full Text].
Rajshekhar V. Surgical management of neurocysticercosis. Int J Surg. 2010. 8(2):100-4. [Medline].
Kelvin EA, Carpio A, Bagiella E, Leslie D, Leon P, Andrews H, et al. Seizure in people with newly diagnosed active or transitional neurocysticercosis. Seizure. 2011 Mar. 20(2):119-25. [Medline]. [Full Text].
Viola GM, White AC Jr, Serpa JA. Hemorrhagic cerebrovascular events and neurocysticercosis: a case report and review of the literature. Am J Trop Med Hyg. 2011 Mar. 84(3):402-5. [Medline]. [Full Text].
Li J, Zhang WB, Wilson M, et al. A novel recombinant antigen for immunodiagnosis of human cystic echinococcosis. J Infect Dis. 2003 Dec 15. 188(12):1952-61. [Medline].